Eprazinone

Eprazinone

SCHEMBL20156

CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
LMNA P02545 4/20 0.57
MC4R P32245 5/20 0.54
MC1R Q01726 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
MITF O75030 3/20 0.50
PAX8 Q06710 2/20 0.50
RAB9A P51151 2/20 0.50
HTT P42858 1/20 0.50
GFER P55789 1/20 0.50
ATM Q13315 1/20 0.50
CHRM2 P08172 2/20 0.48
ADRA2B P18089 2/20 0.48
DRD3 P35462 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
HRH3 Q9Y5N1 2/20 0.48
CYP2D6 P10635 1/20 0.48
ADRA2C P18825 1/20 0.48
CHRM3 P20309 1/20 0.48
OPRD1 P41143 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eprazinone SCHEMBL6429748 0.99 ALDH1A1 (0.56) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
Eprazinone SCHEMBL21807703 0.99 ALDH1A1 (0.60) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
Eprazinone SCHEMBL598430 0.99 ALDH1A1 (0.60) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
Eprazinone SCHEMBL28086760 0.87 ALDH1A1 (0.45) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
Eprazinone SCHEMBL28086279 0.85 LMNA (0.46) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
Eprazinone SCHEMBL1009370 0.78 ALDH1A1 (0.39) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
SCHEMBL12847710 0.78 GAA (0.58) ALDH1A1MC4RCHRM2DRD3CYP2D6
SCHEMBL9170851 0.78 ALDH1A1 (0.73) ALDH1A1LMNAMC4RMC1RSMN1; SMN2
SCHEMBL14791780 0.78 POLB (0.47) ALDH1A1LMNASMN1; SMN2MITFPAX8
SCHEMBL10854331 0.77 CHRM2 (0.75) ALDH1A1LMNAMC4RMC1RSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4631504-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF FABRY'S DISEASE Korea Advanced Institute of Science and Technology (KR) 2025-10-15 EP claimed
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
WO-2024123129-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF FABRY'S DISEASE 한국과학기술원 2024-06-13 WO claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
US-11872307-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2024-01-16 US claimed
EP-3682872-B1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-01-03 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1651184-A1 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS Warner-Lambert Company LLC (US) 2006-05-03 EP claimed
CN-1750809-A Fast dissolving orally consumable films containing pharmaceutically active agents WARNER LAMBERT CO (US) 2006-03-22 CN claimed
WO-2004096174-A1 FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-11 WO claimed
US-20030206942-A1 Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent MCNEIL-PPC, INC 2003-11-06 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0125634-B1 USE OF A SECRETOLYTICALLY ACTIVE SUBSTANCE FOR THE MANUFACTURE OF A REMEDY AGAINST SNORING AND FOR COMBATING SNORE PHENOMENON Reichert, Dietrich, Dr. med. (ES) 1990-09-26 EP claimed